Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. (Q48006996)

7 February 2018

editorial

0 references

title

Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. (English)

1 reference

7 February 2018

polycystic ovary syndrome

main subject

1 reference

1 reference

1 reference

Susan Sam

1

1 reference

7 February 2018

David A Ehrmann

series ordinal

2

1 reference

7 February 2018

publication date

3 August 2017

1 reference

7 February 2018

published in

Diabetologia

1 reference

7 February 2018

volume

60

1 reference

7 February 2018

page(s)

1656-1661

1 reference

7 February 2018

issue

9

1 reference

7 February 2018

https://scigraph.springernature.com/pub.10.1007/s00125-017-4306-3

exact match

0 references

cites work

Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Insulin resistance in nonobese patients with polycystic ovarian disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Androgen levels during sequential insulin euglycemic clamp studies in patients with polycystic ovary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

The role of variants regulating metformin transport and action in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Responsiveness to metformin in girls with androgen excess: collective influence of genetic polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

The mechanisms of action of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

CLINICAL PRACTICE. Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

A Dietary Medium-Chain Fatty Acid, Decanoic Acid, Inhibits Recruitment of Nur77 to the HSD3B2 Promoter In Vitro and Reverses Endocrine and Metabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin has direct effects on human ovarian steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin directly inhibits androgen production in human thecal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00125-017-4306-3

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

21 January 2018

1 reference

12 December 2020

Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome

1 reference

12 December 2020

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART

1 reference

12 December 2020

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

12 December 2020

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

1 reference

12 December 2020

Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens

1 reference

12 December 2020

10.1007/S00125-017-4306-3

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

28770330

1 reference

7 February 2018